ObsEva
Chemin des Aulx, 12
1228 Plan-les-Ouates
Geneva
Website: http://www.obseva.com/
Email: delphine.renaud@obseva.ch
84 articles with ObsEva
-
ObsEva Announces The Completion Of Patient Recruitment In The IMPLANT2 Phase III Clinical Trial In Assisted Reproductive Technology Ahead Of Schedule
9/6/2017
-
ObsEva Reports Second Quarter 2017 Financial Results And Provides Business Update
8/16/2017
-
ObsEva To Hold Second Quarter 2017 Financial Results/Business Update Call On August 15, 2017 And Present At Wedbush Pacgrow Healthcare Conference In NYC On August 16, 2017
8/7/2017
-
ObsEva Announces Presentations Related To Its Assisted Reproductive Technology (ART) And Pre-Term Labor (PTL) Development Programs At ESHRE 2017 Annual Meeting
6/29/2017
-
ObsEva Announces The Completion Of A Phase I PK/PD Clinical Trial Evaluating Different Doses Of OBE2109 And Add-Back Therapy
6/7/2017
-
ObsEva Reports First Quarter 2017 Financial Results and Business Update
5/18/2017
-
ObsEva Announces The Completion Of A Phase I Drug-Drug Interaction Study With OBE022
5/18/2017
-
ObsEva To Hold First Quarter 2017 Financial Results And Business Update Call On Thursday, May 18, 2017
5/11/2017
-
ObsEva Initiates Phase III Clinical Program For OBE2109 In Uterine Fibroids
4/25/2017
-
ObsEva To Present Pharmacology Results Demonstrating OBE022 Exerts A Synergistic Effect In Combination With Standard Of Care In Animal Model For Preterm Labor
3/17/2017
-
ObsEva Starts Phase III Clinical Program For Nolasiban In ART
3/7/2017
-
Women's Health Biotech ObsEva to Open Up U.S. HQ in Boston After $97 Million IPO
1/30/2017
-
ObsEva Release: Pharma To Ring The Nasdaq Stock Market Opening Bell In Celebration Of Its IPO
1/26/2017
-
ObsEva Release: Pharma Announces Pricing Of Initial Public Offering
1/26/2017
-
ObsEva Release: Company Expands Leadership Team And Board Of Directors With Industry Veterans
1/17/2017
-
ObsEva Release: Company Announces Completion Of Phase I First-In-Women Study Of OBE022 For The Treatment Of Preterm Labor
1/13/2017
-
ObsEva Announces Plans To Conduct Initial Public Offering In The United States
10/17/2016
-
ObsEva To Webcast Presentation At 15th Annual Needham Healthcare Conference
4/5/2016
-
ObsEva Strengthens Board With Appointment Of Biotechnology Veteran Dr. Frank Verwiel
3/24/2016
-
ObsEva And Kissei Pharmaceutical Co., Ltd. Announce Global Agreement To Develop And Commercialize KLH-2109 For The Treatment Of Endometriosis
11/20/2015